Company Overview of Hydra Biosciences, Inc.
Hydra Biosciences, Inc., a biopharmaceutical company, engages in the identification and development of therapeutic agents that treat pain, inflammation, anxiety, renal, and pulmonary diseases. The company was founded in 2001 and is based in Cambridge, Massachusetts.
45 Moulton Street
Cambridge, MA 02138
Founded in 2001
Key Executives for Hydra Biosciences, Inc.
Chief Executive Officer, President and Director
Scientific Co-Founder and Member of Scientific Advisory Board - Cardiac Regeneration
Scientific Co-Founder and Member of Scientific Avisory Board - Cardiac Regeneration
Scientific Co-Founder, Chair of Scientific Advisory Board and Member of Pain Medical Advisory Board
Interim Chief Financial Officer
Compensation as of Fiscal Year 2015.
Hydra Biosciences, Inc. Key Developments
Hydra Biosciences Announces Executive Appointments to Newly Created Pain Medical Advisory Board
Jun 4 15
Hydra Biosciences announced newly formed pain medical advisory board (MAB) with the appointments of three leading physicians and scientists, Dr. Robert Dworkin, Dr. Roy Freeman and Dr. Nathaniel Katz. Dr. Paul Goldenheim, member of the Hydra Biosciences Board of Directors and Hydra founder, Dr. David Clapham, chair of the Hydra Scientific Advisory Board, also have seats on the MAB, which will provide clinical and scientific guidance as Hydra continues to develop HX-100, its clinical stage TRPA1 antagonist, in painful diabetic neuropathy. Robert Dworkin, Ph.D., is a professor of anesthesiology, neurology, oncology and psychiatry in the Center for Human Experimental Therapeutics, and director of the Anesthesiology Clinical Research Center at the University of Rochester School of Medicine and Dentistry. Roy Freeman, M.D., is a professor of neurology at Harvard Medical School and director of the Center for Autonomic and Peripheral Nerve Disorders in the Department of Neurology at Beth Israel Deaconess Medical Center in Boston. Dr. Freeman also is chairman of the World Federation of Neurology research group on the autonomic nervous system. Nathaniel Katz, M.D.is a neurologist and pain management specialist with a distinguished career spanning Harvard Medical School, Brigham and Women’s Hospital and Dana-Farber Cancer Institute. Dr. Katz also served as Chair of the Advisory Committee, Anesthesia, Critical Care and Addiction Products Division for the FDA.
Hydra Biosciences, Inc. Presents at Boston CEO Conference, May-27-2015 02:00 PM
Apr 16 15
Hydra Biosciences, Inc. Presents at Boston CEO Conference, May-27-2015 02:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Russell H. Herndon, Chief Executive Officer, President and Director.
Hydra Biosciences Receives Approval from Health Canada to Begin Phase 1 Trial for HX-100
Apr 14 15
Hydra Biosciences announced that Health Canada approved the company’s Clinical Trial Application (CTA) to begin a Phase 1 study of HX-100. This study will provide the safety data necessary for Phase 2 studies in painful diabetic neuropathy (PDN) and allergic asthma that are expected to begin later this year. TRP channels are membrane-bound proteins that play a role in controlling cellular calcium levels and excitability in response to a variety of stimuli. The 28 members of the TRP family differ from better-known ion channels in that they are not primarily voltage gated and have significant sequence diversity, providing the opportunity to develop truly selective modulators. In addition to their well-documented role in pain and pulmonary disorders, TRPs have been linked to CNS, renal and dermatological diseases. TRPA1 is a member of the TRP family, activated by reactive chemicals, products of aberrant glucose metabolism, tissue injury, and inflammation. Environmental irritants that lead to channel activity include common asthma triggers such as cigarette smoke, ozone and chlorine. HX-100 is a highly selective, potent inhibitor of TRPA1. Pre-clinical data demonstrate promising safety and efficacy with several potential advantages over currently available treatments for chronic pain and asthma. HX-100 can be taken orally, and it is expected to have robust efficacy without abuse liabilities, given the limited expression of TRPA1 in the brain. This Phase 1 trial of HX-100 follows a standard single ascending dose and multiple ascending dose design with approximately 90 healthy volunteers. The company expects to initiate separate Phase 2 studies in painful diabetic neuropathy and allergic asthma in late 2015 with results from these trials expected before the end of 2016.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 17, 2015